Search
Epicept NP-1
go.drugbank.com/drugs/DB05492InvestigationalPeripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system.
Furosemide
go.drugbank.com/drugs/DB00695ApprovedInvestigationalVet approved[L7961] It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body.
Oxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigationalOxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. It is a structural derivative of carbamazepine and exerts a majority of its activ...
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigationalIt was developed by Novartis and was granted FDA approval on November 15, 2019.
Enoxacin
go.drugbank.com/drugs/DB00467ApprovedA broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.
Phosphocreatine
go.drugbank.com/drugs/DB13191InvestigationalNutraceuticalPhosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell...
Eugenol
go.drugbank.com/drugs/DB09086ApprovedInvestigationalEugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves.
Pheniprazine
go.drugbank.com/drugs/DB09250ApprovedWithdrawnPheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.
Norgestimate
go.drugbank.com/drugs/DB00957ApprovedInvestigational[A191068] It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects.
Talquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalIt consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]